Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Glaukos Corporation GKOS

Healthcare — Medical Devices

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
68.57
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 2 1 4 1 4 2 4 1 5 4 —
Insider Ownership
3.70%

Capital & Financial Ratios

Market Cap
9,600.00
Revenue
612.84
Net Income
(188.05)
Free Cash Flow
(12.20)
Net Debt
(218.88)
Current Ratio
5.04
Debt/Equity
0.10
P/E ratio
0.00
P/S ratio
15.72
P/B ratio
14.12
Past 5Y EPS Growth
(49.95%)
This Y EPS Growth
65.91%
Next Y EPS Growth
264.40%
Next 5Y EPS Growth
51.45%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 295.43 318.92 278.76 286.23
Receivables 39.85 60.74 108.61 138.90
Inventory 41.99 57.68 63.56 59.31
Other — — — —
395.46 449.79 474.98 515.78
2023 2024 2025 Q'26
Payables 13.44 13.03 24.62 19.14
ST’ Debt — — — —
Other — — — —
74.01 75.13 101.28 102.33
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 150.57 185.61 — —
—
’25 106.66 124.12 133.54 143.12
507.44
’24 85.62 95.69 96.67 105.50
383.48
’23 73.90 80.40 78.05 82.37
314.71
’22 67.68 72.69 71.27 71.23
282.86
’21 67.97 78.09 74.71 73.24
294.01
’20 55.34 31.56 64.83 73.23
224.96
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (12.53) 14.82 — —
—
’25 (18.52) 6.98 (10.09) 6.84
(14.79)
’24 (33.87) (18.37) (9.59) 0.51
(61.32)
’23 (30.76) (8.16) (8.17) (10.66)
(57.76)
’22 9.77 (12.21) (26.51) (4.14)
(33.08)
’21 4.18 7.39 17.79 (4.65)
24.71
’20 (13.10) (10.92) (9.57) 10.60
(22.99)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (16.48) 12.09 — —
—
’25 (20.46) (10.81) (11.72) 3.93
(39.06)
’24 (34.84) (20.48) (11.04) (1.23)
(67.58)
’23 (37.67) (13.93) (11.53) (14.88)
(78.01)
’22 3.23 (21.57) (32.55) (12.30)
(63.20)
’21 (13.00) (3.97) 7.87 (13.98)
(23.07)
’20 (13.88) (13.65) (10.85) 8.46
(29.92)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.34) (0.31) — —
—
’25 (0.32) (0.34) (0.28) (2.32)
(3.28)
’24 (0.82) (1.06) (0.39) (0.60)
(2.77)
’23 (0.72) (0.68) (0.63) (0.75)
(2.78)
’22 0.11 (0.96) (0.58) (0.66)
(2.09)
’21 (0.36) (0.38) 0.13 (0.47)
(1.07)
’20 (1.24) (0.90) (0.35) (0.24)
(2.70)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.33 42.48 74.75 73.16 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 64.49 86.53 153.50 163.71 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 783 907 995 1,094 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.36 0.35 0.39 0.46 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 282.86 314.71 383.48 507.44 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 75.61% 75.99% 75.48% 77.97% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (98.43) (133.73) (145.60) (193.04) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (34.80%) (42.49%) (37.97%) (38.04%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (99.19) (134.66) (146.37) (187.69) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 38.05 37.67 36.60 39.36 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.96 6.50 7.27 8.87 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ (2.09) (2.78) (2.77) (3.28) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.70) (1.19) (1.16) (0.26) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.63) (0.42) (0.12) (0.42) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.33) (1.61) (1.28) (0.68) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.17 9.53 14.54 11.47 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 47.44 48.43 52.76 57.19 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.36 11.86 20.63 12.73 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.93 8.08 10.31 9.84 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.36 12.05 19.98 12.31 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.96) (48.60) (113.36) (159.92) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (33.08) (57.76) (61.32) (14.79) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (30.11) (20.25) (6.26) (24.27) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (63.20) (78.01) (67.58) (39.06) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 371.50 321.45 374.67 373.71 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 353.57 353.31 69.46 68.11 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.88 57.88 (249.45) (210.65) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 530.01 461.77 766.93 656.16 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (9.67%) (13.86%) (15.29%) (20.09%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (9.69%) (15.48%) (14.78%) (28.00%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.76%) (27.16%) (23.83%) (26.38%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Glaukos Corporation (GKOS), a specialist in glaucoma treatments like the iStent platform, dazzles investors with robust revenue growth—up 13% CAGR to $383 million in 2024 and projected to hit $783 million by 2027—but this masks chronic cash burn, negative free cash flow, and elusive profitability. A devastating 2020 FDA warning letter triggered a gross margin plunge from 83.7% to 59.2%, exposing operational vulnerabilities that persist today with margins stuck at 75.5% and EPS deeply negative at -$2.77. Diluted shares have ballooned 60%, insiders are cashing out over $38 million with zero buys, and sky-high valuations (20x sales, 10x book) scream overoptimism amid eroding fundamentals.

The stock’s rollercoaster—from $154 highs in 2024 to recent pullbacks—reflects hype around revenue beats clashing with reality: ROIC at -14.8%, ROE at -23.8%, and net debt climbing. Analysts project an EPS turnaround to positive by 2027 and FCF inflection, fueling 19% average upside targets, but risks like regulatory hurdles, fierce competition from Alcon and J&J, and scaling costs loom large.

This contrarian take warns GKOS is no growth rocket but a high-beta gamble priced for perfection—one glitch could send it tumbling. Dive into the full analysis for the numbers that could make or break your bet on this glaucoma innovator.

Read full commentary →

Glaukos Corporation (GKOS) Latest News

News by impact score

Fine-tune

20 Aug

4 , 11:54 AM
Glaukos Corporation stock surges 67% year to date on factors driving the rally. 67% year-to-date surge indicates major positive developments with significant effects on future trajectory and sentiment.

7 Aug

4 transcript www.fool.com, 8:35 PM
Glaukos (GKOS) released its Q2 2026 earnings call transcript covering quarterly financial results, operational updates, and forward guidance. Earnings call transcripts deliver key financial metrics and outlook that drive major shifts in valuation and investor positioning.

31 Jul

4 , 5:09 AM
Glaukos reported record sales and raised guidance, raising questions on whether its stock is overvalued. Record sales and raised guidance reflect strong core performance likely to shift company trajectory and sentiment.

4 , 3:08 AM
Glaukos raised 2026 sales guidance and advanced its PRESERFLO study, driving an immediate 10.8% stock gain. Raised multi-year sales targets plus PRESERFLO advancement indicate material upside to revenue trajectory and competitive positioning.

30 Jul

4 , 11:55 AM
Glaukos Q2 earnings beat estimates driven by iDose TR growth, lifting the stock price. Q2 earnings beat on iDose TR growth signals robust revenue increase and enhanced market position for Glaukos.

4 , 1:03 AM
Glaukos reports record Q2 2026 revenue surge and raises guidance. Record revenue surge plus raised guidance marks major positive shift in financial trajectory.

3 transcript app.moby.co, 8:30 AM
Glaukos Corporation released its Q2 2026 earnings call summary covering financial results, operational updates and forward guidance. Quarterly earnings updates typically influence near-term sentiment and valuation but rarely trigger lasting strategic shifts.

3 transcript www.marketbeat.com, 12:03 AM
Glaukos Q2 earnings call covered financial results, product pipeline updates, revenue guidance, and strategic initiatives for the ophthalmic medical device company. Q2 earnings details and guidance offer moderate insight into near-term financial trajectory and operational priorities.

29 Jul

3 , 10:30 PM
Glaukos Corporation released Q2 earnings results with analysis of key financial metrics. Q2 earnings and metrics release informs near-term financial outlook and investor views without indicating major strategic shifts.

3 , 4:05 PM
Glaukos Corporation reported second quarter 2026 financial results. Quarterly earnings release supplies performance data that affects valuation and sentiment but does not alter strategy or competitive position.

27 Jul

3 , 7:00 AM
Glaukos Corporation completed patient enrollment in its 510(k) pivotal study for the PRESERFLO MicroShunt. Enrollment completion advances regulatory progress for PRESERFLO MicroShunt toward potential approval.

8 Jul

3 , 2:04 PM
Glaukos Corporation stock rises over 45% since May-end on factors driving the rally. Stock rally reflects positive momentum but lacks details on transformative events altering long-term trajectory.

3 , 12:22 PM
Glaukos Corporation maintains focus on profitability while operating in the glaucoma therapy sector. Emphasis on profits points to steady financial positioning that may moderately support market perception.

3 May

4 Simply Wall St., 10:13 PM
Glaukos Corporation (GKOS) investment narrative shifts with new guidance and elevated product ramp expectations. New guidance and product ramp expectations represent major shifts in GKOS's growth trajectory and investor sentiment.

30 Apr

4 Zacks, 10:53 AM
Glaukos Corporation (GKOS) shares rose after reporting a Q1 earnings beat and issuing an improved revenue outlook for 2026. Q1 earnings beat combined with upgraded 2026 revenue outlook boosts investor confidence and signals stronger long-term growth trajectory.

4 www.marketbeat.com, 4:05 AM
Glaukos Corporation reported Q1 revenue of $86.0 million, up 14% year-over-year and beating estimates. Net loss narrowed to $28.1 million from $34.6 million. Glaucoma franchise drove growth with iStent sales up 16%; corneal health segment gained traction. Full-year 2024 revenue guidance raised to $375-$382 million. Pipeline advancements include iDose TR Phase 3 progress and new product launches planned. Earnings beat, narrowed losses, and raised full-year guidance indicate significant positive momentum for financial performance and growth trajectory.

4 GuruFocus.com, 3:17 AM
Glaukos Corp (GKOS) reported record Q1 2026 sales surge and raised full-year guidance in earnings call highlights. Record sales surge and raised guidance signal strong growth, significantly boosting future performance and investor sentiment.

29 Apr

4 Zacks, 9:00 PM
Glaukos (GKOS) Q1 earnings key metrics compared to estimates, highlighting performance against analyst expectations. Q1 earnings metrics versus estimates signal financial health and drive substantial shifts in GKOS stock trajectory and investor confidence.

4 app.moby.co, 8:26 PM
Glaukos Corporation released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 earnings call summary reveals key financial metrics and outlook that significantly shape investor expectations and stock performance.

4 Business Wire, 4:05 PM
Glaukos Corporation announced first quarter 2026 financial results. Quarterly financial results represent a major update on revenue, profitability, and guidance that can significantly alter investor sentiment and stock trajectory.

3 Zacks, 6:40 PM
Glaukos (GKOS) reported a Q1 net loss but exceeded revenue estimates. Q1 loss despite revenue beat delivers mixed financial results with moderate effects on financial performance and investor sentiment.

16 Apr

4 Zacks, 10:22 AM
Glaukos Corporation secures permanent J-Code for Epioxa, its Keratoconus therapy, enabling standardized Medicare reimbursement and broader market access. Permanent J-Code approval streamlines Medicare reimbursement for Epioxa, driving adoption and revenue growth in Glaukos' ophthalmology portfolio.

15 Apr

4 Business Wire, 4:05 PM
Glaukos Corporation received a permanent J-code from CMS for Epioxa™, its riboflavin ophthalmic solution used in corneal cross-linking procedures for keratoconus treatment, effective October 1, 2024, streamlining Medicare reimbursement and commercial adoption. Permanent J-code assignment accelerates Epioxa™ reimbursement and market uptake, significantly impacting Glaukos' revenue growth and competitive position in ophthalmology.

6 Apr

3 Simply Wall St., 11:08 PM
Glaukos Corporation showcased Epioxa at the ASCRS meeting, potentially signaling a strategic shift toward broader corneal health initiatives beyond its core glaucoma focus. Epioxa presentation at ASCRS hints at corneal health expansion, moderately impacting strategic positioning and market sentiment.

20 Mar

4 Zacks, 9:33 AM
Glaukos Corporation launches Epioxa, a new treatment boosting growth in corneal therapies. Epioxa launch is a major product introduction expanding Glaukos' corneal treatment portfolio and driving significant growth.

19 Mar

4 Business Wire, 7:00 AM
Glaukos Corporation announces commercial availability of Epioxa™, a transformative innovation in interventional keratoconus care. Commercial launch of Epioxa™ as a transformative product in keratoconus care signals major innovation driving Glaukos' growth and competitive edge.

3 Zacks, 11:30 AM
Glaukos Corporation (GKOS) shares plunged 14.7% since the last earnings report amid weak financial results, including missed revenue and EPS expectations, rising expenses, and concerns over iDose TR commercialization delays. Post-earnings miss and commercialization hurdles are expected to moderately influence financial performance and investor sentiment.

26 Feb

3 Simply Wall St.Associated Press FinanceGuruFocus.comSimply Wall St.ZacksMarketBeatMobyInsider Monkey, 3:16 AM
Glaukos Corporation sets ambitious 2026 sales target while filing ESOP shelf registration, raising questions on whether investors need to take action. Ambitious 2026 sales target could moderately shape financial expectations and investor sentiment, balanced by routine ESOP filing.

23 Feb

4 Insider Monkey, 8:28 AM
Glaukos Corporation (GKOS) posted strong Q4 results with 38.1% revenue growth, lifting its stock performance. 38.1% Q4 revenue growth demonstrates significant financial momentum and positive investor sentiment for GKOS trajectory.

19 Feb

4 app.moby.co, 8:08 PM
Glaukos Corporation reported Q4 2025 earnings call highlights, including financial results, revenue growth, pipeline advancements, and 2026 guidance. Q4 year-end earnings summary delivers key financial metrics and forward outlook that significantly shape investor expectations and stock trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us